Intravitreal drug delivery has become the gold standard for treating many retinal diseases, first and foremost, neovascular age-related macular degeneration (AMD), diabetic macular oedema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO). The frequency of intravitreal injections during the day in clinical practice has significantly increased since the introduction of anti-vascular endothelial growth factor (VEGF) medications 18 years ago. An ageing population due to demographic change, as well as common diseases such as diabetes and cardiovascular complications, are leading to an increased number of patients with retinal diseases that can be effectively treated with anti-VEGF therapies. The technique of intravitreal injections must be mastered to allow a reliable flow of the daily organisational routine of surgery, sterility and, above all, patient safety. Nowadays, various products are available on the market (Lucentis^®, Eylea^®, Beovu^®, Ozurdex^® and Vabysmo^®) that are either injected directly with pre-filled syringes or withdrawn beforehand from glass containers with transfer needles and then applied with injection needles. Either way, the techniques involved in adequately performing the procedures are essential to master to optimise patient safety and avoid the risk of complications.

PD Dr. Katja Hatz Vista Klinik AG
PD Dr Maria Della Volpe Augenklinik Heuberger Olten
Dr Wael Abou Hadeed Vista Augenklinik Zürich
PD Dr Mayss Al-Sheikh Universitätsspital Zürich
PD Dr Aude Ambresin RétinElysée Lausanne
Experts from industry: AbbVie AG, Bayer (Schweiz) AG, Novartis Pharma (Schweiz) AG and Roche Pharma (Schweiz) AG

KKL Kultur- und Kongresszentrum Luzern

Date: 3^rd March 2023
Language: English or German
Theory (Deuxième Saal)
Free entry
14:20 – 16:00
Hands on (Clubräume)
Ticket requested
16:00 – 17:30

For further informations please contact michele.guerra@saoo.ch